logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

The forum, organised by the Menéndez Pelayo International University (UIMP) and Farmaindustria, will be held on 7 and 8 September in Santander

Patient representatives, drug authorities, experts in economics and legislation and pharmaceutical companies will participate

Source: farmaindustria.es

The proposed revision of the European pharmaceutical legislation published at the end of April by the European Commission (EC) contains a number of measures that could jeopardise the development of the pharmaceutical industry on our continent and patients’ access to innovative treatments.

Biopharmaceutical companies are particularly concerned because the initial approach weakens incentives for investment in innovation and thus hinders the development of new medicines in Europe. However, the road ahead for the reform of pharmaceutical legislation has only just begun, so constructive and in-depth discussions on amending the legislation can be very fruitful in improving some aspects of the proposal and making the European Union (EU) a more conducive territory for investment in R&D and biomedical production.

This is what has motivated the 22nd Meeting of the Spanish Pharmaceutical Industry, organised as every year by the Menéndez Pelayo International University (UIMP) and Farmaindustria, to focus on analysing the EC proposal and its impact on Spain and European patients.

The meeting, which will take place in Santander on Thursday 7 and Friday 8 September under the title Perspectives on drug regulation and incentives for pharmaceutical R&D, will be attended by representatives of the Spanish Medicines Agency (Aemps), patients and pharmaceutical companies, authorities and experts in economics and legislation. Among the confirmed specialists are Nathalie Moll, Director General of the European Federation of the Pharmaceutical Industry (Efpia), and Georges Siotis, former Economic Advisor to the EC, Professor of Economics at the Carlos III University in Madrid, and Associate Researcher in the Industrial Organisation Programme.

As in previous editions, the Meeting is directed by Félix Lobo, Emeritus Professor at the Carlos III University, Madrid, Director of Economics and Health Policies at Funcas and President of the Advisory Committee of the Pharmaceutical Provision of the NHS of the Ministry of Health. The agenda for both days can be found at this link.

“Investment in research and development of new medicines is shifting to the United States and China, which in the last 20 years have increased their investment in this field to the detriment of Europe. Currently, only 22% of new treatments originate in our continent, while 47% come from North America,” recalls Farmaindustria’s director general, Juan Yermo. This loss of European competitiveness compared to other markets that have shown greater growth”, he adds, “has a direct implication for European and Spanish citizens, as access to the best treatments or the possibility of participating in innovative clinical trials is at risk”.

 

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.